Since the news that Turing Pharmaceuticals had jacked up the price of the drug Daraprim by 5,000% broke in September, former CEO Martin Shkreli has become perhaps the most-hated public figure in America, resigned from his job and been arrested on civil and criminal securities fraud charges.

While much has changed in Shkreli’s life, when he testifies before the House Committee on Oversight and Government Reform on Thursday—where he’s said he’ll take the fifth—those who use Daraprim will be paying the exact same price they’ve paid for the last four months: $750 per pill.

Fresh from drubbings in the press and presidential candidates, Shkreli said in late September that he would cut the cost of the drug, which cost $13.50 a pop before Turing acquired it and which many patients must take daily for years.

He didn’t say how much the price would be lowered, but it didn’t matter—he would swiftly renege on is promise. In late November, Turing announced discounts of up to 50% for hospitals—where only patients requiring hospitalization would benefit from the reduction—along with smaller, less costly bottles of the drug.

The embattled biopharmaceutical company sought to portray its price hike as costly only to insurance companies and not consumers, according to documents in a memo released Tuesday by Democratic staff of the House Committee on Oversight and Government Reform.

Read: ‘$1bn here we come.’ — Martin Shkreli told Turing board as Daraprim buy got closer

The company also established patient assistance programs to take the focus away from what a 5,000% increase in price seemed likely to do to patient access, said the memo, which summarized more than 250,000 pages of Turing documents.

But patients were still slapped with co-pays ranging from $1,000 to even more than $16,000, according to the memo.

Access to the drug has also been impeded on the state level, where health departments—normally eligible for discounted Medicaid rates on drugs—have had difficulty gaining access, said Sean Dickson, manager of health care access at the National Alliance of State and Territorial AIDS Directors.

And while hospitals can get discounted access to Daraprim, those terms are negotiated individually, and would only benefit patients getting initial treatment with the drug.

Daraprim is used to treat parasitic infections and prevent a nervous system infection in those with HIV.

Read: Learn all about Martin Shkreli from Martin Shkreli himself

How, four months later, are customers still facing a list price that has been near-universally condemned?

“They just obviously are looking to maximize profits,” said Dickson.

Turing did not immediately respond to a request for comment.